Public Employees Retirement System of Ohio Cuts Holdings in Integra LifeSciences Holdings Corporation $IART

Public Employees Retirement System of Ohio trimmed its position in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 96.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,692 shares of the life sciences company’s stock after selling 71,414 shares during the period. Public Employees Retirement System of Ohio’s holdings in Integra LifeSciences were worth $33,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of IART. MassMutual Private Wealth & Trust FSB boosted its stake in Integra LifeSciences by 6,017.6% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 10,094 shares of the life sciences company’s stock valued at $124,000 after acquiring an additional 9,929 shares in the last quarter. CWM LLC boosted its stake in Integra LifeSciences by 413.8% in the first quarter. CWM LLC now owns 6,664 shares of the life sciences company’s stock valued at $147,000 after acquiring an additional 5,367 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in Integra LifeSciences by 16.9% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 13,352 shares of the life sciences company’s stock valued at $180,000 after acquiring an additional 1,927 shares in the last quarter. Teacher Retirement System of Texas acquired a new stake in Integra LifeSciences in the first quarter valued at approximately $223,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in Integra LifeSciences in the first quarter valued at approximately $277,000. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on IART shares. Citigroup restated a “sell” rating and issued a $12.00 target price (up from $10.00) on shares of Integra LifeSciences in a research note on Tuesday. Weiss Ratings reiterated a “sell (d)” rating on shares of Integra LifeSciences in a research note on Wednesday. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and four have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus price target of $16.83.

Integra LifeSciences Trading Up 2.6%

NASDAQ IART opened at $14.81 on Thursday. The company has a market capitalization of $1.15 billion, a PE ratio of -2.27 and a beta of 1.21. The company has a fifty day moving average of $14.29 and a 200 day moving average of $14.50. Integra LifeSciences Holdings Corporation has a 1 year low of $11.06 and a 1 year high of $27.13. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.23 and a quick ratio of 0.73.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Thursday, July 31st. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.43 by $0.02. The company had revenue of $415.61 million during the quarter, compared to the consensus estimate of $395.06 million. Integra LifeSciences had a negative net margin of 30.87% and a positive return on equity of 12.15%. The firm’s quarterly revenue was down .6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.63 earnings per share. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. Research analysts forecast that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.